Tempus Pixel vs iPredict Eye Screening

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Tempus Pixel
VS
by iHealthScreen

AI Verdict

Tempus Pixel is a multi-modality diagnostic imaging analysis platform for cardiology, oncology, and neurology, designed to enhance workflow and accuracy for radiologists and clinicians. In contrast, iPredict Eye Screening is a specialized AI tool focused on screening for specific eye diseases like AMD, DR, and Glaucoma, and predicting systemic disease risks based on retinal imaging. While both leverage AI in healthcare and integrate with EHRs, their primary clinical applications and target specialties are distinct.

Choose Tempus Pixel if…

Choose Tempus Pixel if your institution requires an advanced, multi-modality AI platform for in-depth medical imaging analysis across cardiology, oncology, and neurology. This tool is ideal for radiologists and specialists seeking to enhance diagnostic accuracy, leverage 3D visualization, and streamline complex image interpretation workflows with automated reporting and real-time collaboration.

View Tempus Pixel →

Choose iPredict Eye Screening if…

Choose iPredict Eye Screening if your primary care clinic or telemedicine service needs a fast, easy-to-operate AI solution for early detection of common eye diseases like AMD, DR, and Glaucoma. This platform is best suited for broad patient screening, particularly for those aged 50 and older, and offers the added benefit of predicting systemic disease risks like stroke and heart attack, integrating seamlessly into routine check-ups.

View iPredict Eye Screening →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Tempus Pixel iPredict Eye Screening
Pricing Unknown Contact for pricing
Deployment Cloud-based Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps.
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

iPredict Eye Screening

Tool B emphasizes ease of operation, a non-invasive approach, an advanced touchscreen interface, and rapid results (under 5 minutes for the test, under 60 seconds for the report), making it highly user-friendly for a broader range of clinical staff, particularly in primary care settings. Tool A, while offering advanced features, appears more tailored to specialized radiological workflows.

Clinical Value

iPredict Eye Screening

Both tools are FDA-cleared and offer significant clinical benefits. However, Tool B provides explicit high accuracy percentages for its screening capabilities (approx. 95% average, AMD sensitivity 86.86%, specificity 94.13%) and uniquely extends its value by offering risk prediction for systemic diseases like stroke and heart attack alongside eye screening. This broader preventative scope and quantifiable accuracy give it an edge.

Pricing & Value

iPredict Eye Screening

Tool B offers greater transparency in its pricing model, detailing a per-patient screening on a SaaS model with an estimated cost of $10-$20 per patient, linked to Medicare/commercial payor reimbursement. This provides potential customers with a clearer understanding of the financial investment and potential ROI compared to Tool A's 'contact for quote' approach.

Enterprise Readiness

Tempus Pixel

Both tools are FDA-cleared, HIPAA compliant, and cloud-based, indicating strong foundational readiness. However, Tool A explicitly lists integration with existing PACS, EHR, and RIS environments, which are comprehensive enterprise systems for radiology and broader hospital workflows. Additionally, Tempus, as the parent company, is a larger and more established entity in healthcare AI, suggesting more robust enterprise support and infrastructure.

Innovation

iPredict Eye Screening

While both leverage AI, Tool B demonstrates a higher degree of innovation by combining multi-disease retinal screening with a unique online health risk prediction system for systemic conditions such as stroke and heart attack. This integrated approach to preventative health and broader risk assessment extends beyond traditional diagnostic enhancement.

Support & Docs

Tempus Pixel

Tempus (Tool A) provides more comprehensive support resources, including multiple contact channels via email and phone, and a publicly accessible 'Document Library' with various guides and system requirements for Tempus Pixel. While iHealthScreen (Tool B) offers contact information and mentions training, the breadth of documented resources appears less extensive.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Tempus Pixel iPredict Eye Screening
Name Tempus Pixel iPredict Eye Screening
Company Tempus (formerly Arterys) iHealthScreen
Tagline The future of precision medicine that only human + AI can achieve. AI-powered screening tools for early detection of retinal and systemic diseases.
Primary AI Categories Cardiology AI Cardiology AI, Neurology AI, Ophthalmology AI
Key Features (General) AI-powered analysis, Cloud-based platform, Real-time collaboration, Multi-modality support (MRI, CT, X-ray, ultrasound), Automated reporting, 3D visualization, Quantitative analysis, DICOM compatibility. AI-Based Screening, Electronic Health Record (EHR) Solutions, AI-Based Telemedicine Service, Image Analyzer, Online Health Risk Prediction System, Fast results, High accuracy, Easy to operate, non-invasive, with an advanced touchscreen interface.
Specific Disease Screening/Analysis Enhances diagnostic accuracy and workflow efficiency for radiologists and clinicians across cardiology, oncology, and neurology. AI-powered screening tool for age-related macular degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma. Also provides risk prediction for systemic diseases like stroke and heart attack.

Videos

Demos, reviews, and walkthroughs featuring Tempus Pixel and iPredict Eye Screening.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tempus Pixel is an AI-powered medical imaging analysis platform designed to enhance diagnostic accuracy across cardiology, oncology, and neurology, supporting radiologists and clinicians. In contrast, iPredict Eye Screening is an AI-powered screening tool focused on the early detection of age-related macular degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma, primarily for specialties like Family Medicine, Internal Medicine, and Ophthalmology.
Tempus Pixel offers multi-modality support, capable of analyzing MRI, CT, X-ray, and ultrasound images. iPredict Eye Screening focuses on retinal images, utilizing an image analyzer for retinal vessel, retinal pathology, and OCT Inspector.
Tempus Pixel is cloud-based and web-accessible, designed to integrate with existing PACS, EHR, and RIS environments. iPredict Eye Screening is also cloud-based and integrates with EHR and telemedicine services, accessible in various settings including primary care, clinics, and hospitals.
iPredict Eye Screening highlights its efficiency, with tests completed in less than 5 minutes and reports generated in under 60 seconds. Tempus Pixel emphasizes workflow efficiency and automated reporting, but specific turnaround times for its analysis are not detailed in the provided information.
Tempus Pixel offers real-time collaboration features and 3D visualization for its imaging analysis. iPredict Eye Screening provides an online health risk prediction system for systemic diseases like stroke and heart attack, in addition to its eye disease screening capabilities.
Tempus Pixel is an FDA-cleared medical imaging analysis platform for general use across cardiology, oncology, and neurology. iPredict Eye Screening is FDA-cleared specifically for screening age-related macular degeneration (AMD) in patients aged 50 years and older, as well as for Diabetic Retinopathy (DR) and Glaucoma.
AI Tool Finder
AI-powered search. Results may not be comprehensive.